According to sources: “He is exceptionally sharp and has a deep understanding of corporate law.”Chambers USA 2021

Haim Zaltzman

San Francisco | Silicon Valley
  • 505 Montgomery Street
  • Suite 2000
  • San Francisco, CA 94111-6538
  • USA

Haim Zaltzman, chair of Latham & Watkins' San Francisco Bay Area Finance Practice, focuses primarily on healthcare and technology-related private equity, growth equity, and emerging growth financing transactions.

Mr. Zaltzman frequently represents borrowers/issuers, sponsors, and financial institutions in debt financing transactions, including billions of dollars in:

  • Growth debt (venture, structured, royalty, and lower middle market)
  • Private equity and growth equity financings (acquisitions, add-ons, refinancings, etc.)
  • Leasing and other similar asset-based transactions 
  • Structured equity and pre-IPO financings 

Mr. Zaltzman holds leadership positions with the Chinese American International School, Seven Tepees Youth Program for urban youth, the American Jewish Committee, and the Idaho Anne Frank Memorial.    

Mr. Zaltzman has also been featured on CNBC, Bloomberg, The Washington Post, CFO Magazine, The Recorder,, The Daily Journal, the International Financial Law Review, and for his debt expertise.


Mr. Zaltzman's representative transactions include:

  • Hundreds of growth companies in every kind of financing, including recently Brilliant Earth, Impossible Foods, Phononic, Aimmune, Ouster, Postmates, Atec Spine, Menlo Therapeutics, Zogenix, Codexis, Akebia, Seres, Syndax, Axovant, Urovant, Dermavant, BridgeBio, Esperion, Indigo, Achaogen, Relypsa, Phathom, Mesoblast, Radius, Centrexion, Aimmune, Imprimis, CardioFocus, Axcella, Apollo Endo, Kindred Bio, Vapotherm, Eidos, Codiak, Replimune, TG Thera, Opendoor, Zymergen, Upstart, Root Insurance, CradlePoint, RigUp, and many others 
  • OpenDoor, Inc. in the largest tech deSPAC transaction ever
  • The lending arm of top private equity firm in structured debt financings of late stage growth companies
  • A leading hedge fund in tens of structured debt transactions 
  • A publicly traded business development company in tens of structured debt and venture debt transactions     
  • Various private equity sponsored portfolio companies in growth stage and lower middle market debt transactions provided by hedge funds and institutional investors 
  • Multiple late stage sponsors such as Dragoneer Investment Group, Khosla Ventures, Foundation Capital, Mayfield Fund, NewView Capital, Brookfield Ventures, Andreessen Horowitz, KKR, TCV, and others in various growth facilities at their funds and for numerous of their portfolio companies
  • Multiple lenders in tens of debt and equity financings of technology and life sciences companies
Prior Professional Experience
  • Former Editor of the Stanford Journal of International Relations
  • Fulbright Scholar in Russia
  • Prior to Latham & Watkins, attorney in the New York office of Skadden, Arps, Slate, Meagher & Flom LLP
Thought Leadership
  • Emerging Growth Debt, Venture Capital General Counsel Meeting, Boulder, Colorado, March 29-30, 2017
  • Financing Emerging Growth Companies with Debt, Webcast, May 4, 2017
  • The Healthcare & Technology Industries’ Burgeoning Emerging Growth Debt Market, March 13, 2015
  • When Venture Funding is Debt, Not Equity, June 22, 2011
  • After the Credit Crunch: Venture Credit Facilities at the Term Sheet Stage, June 20, 2011
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.